Age-Related Variation in the Provision of Primary Care Services and Medication Prescriptions for Patients with Cardiovascular Disease
- PMID: 36078474
- PMCID: PMC9518583
- DOI: 10.3390/ijerph191710761
Age-Related Variation in the Provision of Primary Care Services and Medication Prescriptions for Patients with Cardiovascular Disease
Abstract
As population aging progresses, demands of patients with cardiovascular diseases (CVD) on the primary care services is inevitably increased. However, the utilisation of primary care services across varying age groups is unknown. The study aims to explore age-related variations in provision of chronic disease management plans, mental health care, guideline-indicated cardiovascular medications and influenza vaccination among patients with CVD over differing ages presenting to primary care. Data for patients with CVD were extracted from 50 Australian general practices. Logistic regression, accounting for covariates and clustering effects by practices, was used for statistical analysis. Of the 14,602 patients with CVD (mean age, 72.5 years), patients aged 65-74, 75-84 and ≥85 years were significantly more likely to have a GP management plan prepared (adjusted odds ratio (aOR): 1.6, 1.88 and 1.55, respectively, p < 0.05), have a formal team care arrangement (aOR: 1.49, 1.8, 1.65, respectively, p < 0.05) and have a review of either (aOR: 1.63, 2.09, 1.93, respectively, p < 0.05) than those < 65 years. Patients aged ≥ 65 years were more likely to be prescribed blood-pressure-lowering medications and to be vaccinated for influenza. However, the adjusted odds of being prescribed lipid-lowering and antiplatelet medications and receiving mental health care were significantly lowest among patients ≥ 85 years. There are age-related variations in provision of primary care services and pharmacological therapy. GPs are targeting care plans to older people who are more likely to have long-term conditions and complex needs.
Keywords: age; cardiovascular disease; primary care; risk factors; secondary prevention.
Conflict of interest statement
T.U. received research grants support from NHMRC and MRFF and received consulting fees from NPS MedicineWise. RG received NHMRC Solve-CHD Synergy Grant. N.Z. received grants from Australian National Health and Medical Research Council. KH received grants from NHMRC Investigator Grant (Emerging leadership). J.R. hold a fellowship from the NHMRC (GNT2007946). E.R.A. received grants from National Heart Foundation Australia-Vanguard Grant 2019. D.H. received research funds from Vifor and Lundbeck, and consulting fees from Pfizer, Amgen, Boehringer-Ingelheim, Novartis, Sanofi and Bayer. C.K.C. received NHMRC Investigator grant. C.H. received research grants from NHMRC, RACGP Foundation, HCF, Sanofi, Amgen, and Heart Research Institute. C.H. received consulting fees under sponsorship of Boehringer Ingelheim, Novo Nordisk, Pfizer, Amgen and PSA, and Gratuity payments for membership on GP Advisory Boards for Pfizer, Amgen, Astra, Zeneca, GSK and Novartis. M.W. is a consultant to Amgen, Freeline and Kyowa Kirin.
References
-
- World Health Organisation Cardiovascular Diseases. 2021. [(accessed on 24 February 2022)]. Available online: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1.
-
- World Health Organisation Aging Geneva. 2021. [(accessed on 24 February 2022)]. Available online: https://www.who.int/health-topics/ageing#tab=tab_1.
-
- World Heart Federation What is Cardiovascular Disease? 2021. [(accessed on 24 February 2022)]. Available online: https://world-heart-federation.org/what-is-cvd/
-
- Perk J., De Backer G., Gohlke H., Graham I., Reiner Ž., Verschuren M., Albus C., Benlian P., Boysen G., Cifkova R. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2012;33:1635–1701. - PubMed
-
- Woodruffe S., Neubeck L., Clark R.A., Gray K., Ferry C., Finan J., Sanderson S., Briffa T.G. Australian Cardiovascular Health and Rehabilitation Association (ACRA) core components of cardiovascular disease secondary prevention and cardiac rehabilitation 2014. Heart Lung Circ. 2015;24:430–441. doi: 10.1016/j.hlc.2014.12.008. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
